Philip Neustrom
The TOGETHER Trial is a clinical trial platform evaluating repurposed drugs for early treatment of COVID-19. The TOGETHER Trial's aim is to discover if existing medications can be used to treat people with early-diagnosed COVID-19.
To date, the TOGETHER Trial has identified two potentially effective medications for COVID-19: Fluvoxamine and Peginterferon Lambda.
The TOGETHER Trial was initiated on June of 2020. On January 20, 2021, TOGETHER enrolled its first patient.
The TOGETHER Trial is a multi-platform, randomized, adaptive trial. The co-principal investigators of TOGETHER are Dr. Edward Mills and Dr. Gilmar Reis.
Drugs trialed
- Hydroxychloroquine - effect not found, arm stopped. See trial results paper.
- Lopinavir/Ritonavir - effect not found, arm stopped. See trial results paper.
- Ivermectin - effect not found, arm stopped.
- Metformin - effect not found, arm stopped. See trial results paper.
- Fluvoxamine - intervention found effective. See trial results paper.
- Peginterferon Lambda - intervention found effective.
- Doxazosin - recruitment paused.
Links
- togethertrial.com - website for the TOGETHER trial. Includes trial protocol design, statistical analysis plan and other information.
- TOGETHER Trial on Twitter.
